SG10201610072UA - Genotype- or phenotype-based drug formulation - Google Patents

Genotype- or phenotype-based drug formulation

Info

Publication number: SG10201610072UA
Authority: SG; Singapore
Prior art keywords: genotype; phenotype; drug formulation; based drug; formulation
Prior art date: 2012-06-01

Application number

SG10201610072UA

Inventor

Stefan Willmann

Thomas Eissing

Kristin Dickschen

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-01

Filing date

2013-05-27

Publication date

2017-01-27

2013-05-27 Application filed by Bayer Ag filed Critical Bayer Ag

2017-01-27 Publication of SG10201610072UA publication Critical patent/SG10201610072UA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physics & Mathematics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Computational Biology (AREA)
Theoretical Computer Science (AREA)
Spectroscopy & Molecular Physics (AREA)
Medical Informatics (AREA)
Evolutionary Biology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Physiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Pregnancy & Childbirth (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SG10201610072UA 2012-06-01 2013-05-27 Genotype- or phenotype-based drug formulation SG10201610072UA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP12170401.9A EP2668945A1 (en)	2012-06-01	2012-06-01	Genotype and phenotype-based medicinal formulations

Publications (1)

Publication Number	Publication Date
SG10201610072UA true SG10201610072UA (en)	2017-01-27

Family

ID=48520964

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201610072UA SG10201610072UA (en)	2012-06-01	2013-05-27	Genotype- or phenotype-based drug formulation
SG11201407791VA SG11201407791VA (en)	2012-06-01	2013-05-27	Genotype- or phenotype-based drug formulation

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201407791VA SG11201407791VA (en)	2012-06-01	2013-05-27	Genotype- or phenotype-based drug formulation

Country Status (23)

Country	Link
US (3)	US10285958B2 (en)
EP (2)	EP2668945A1 (en)
JP (2)	JP6096289B2 (en)
KR (1)	KR102129043B1 (en)
CN (2)	CN110075097A (en)
AR (2)	AR091234A1 (en)
AU (1)	AU2013269793B2 (en)
BR (1)	BR112014030059B1 (en)
CA (1)	CA2875189C (en)
DK (1)	DK2854789T3 (en)
ES (1)	ES2744306T3 (en)
HK (1)	HK1207296A1 (en)
HU (1)	HUE045699T2 (en)
IL (1)	IL235988B (en)
MX (1)	MX370304B (en)
NZ (1)	NZ702849A (en)
PL (1)	PL2854789T3 (en)
PT (1)	PT2854789T (en)
RU (1)	RU2683260C2 (en)
SA (1)	SA113340607B1 (en)
SG (2)	SG10201610072UA (en)
TW (1)	TWI644666B (en)
WO (1)	WO2013178565A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2668945A1 (en) *	2012-06-01	2013-12-04	Bayer Technology Services GmbH	Genotype and phenotype-based medicinal formulations
US11965206B2 (en)	2018-12-21	2024-04-23	John Stoddard	Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1317546C (en) *	1985-07-01	1993-05-11	Werner Meier	Pharmaceutical preparations containing mixtures of hydroxy derivatives of vitamin d
US6048857A (en)	1989-10-17	2000-04-11	Ellinwood, Jr.; Everett H.	Dosing method of administering medicaments via inhalation administration
US5580728A (en)	1994-06-17	1996-12-03	Perlin; Mark W.	Method and system for genotyping
US6017963A (en) *	1995-11-14	2000-01-25	Euro-Celtique, S.A.	Formulation for intranasal administration
US6760708B1 (en)	1999-08-19	2004-07-06	Dell Products L.P.	Method and system for migrating stored data to a build-to-order computing system
EP1248832A4 (en)	2000-01-21	2004-07-07	Variagenics Inc	IDENTIFICATION OF GENETIC COMPONENTS IN DRUG REACTION
US7427480B2 (en)	2002-03-26	2008-09-23	Perlegen Sciences, Inc.	Life sciences business systems and methods
JP2007504131A (en) *	2003-08-29	2007-03-01	エートンファーマインコーポレーティッド	Combination treatment of cancer
US7504214B2 (en) *	2003-09-19	2009-03-17	Biotheranostics, Inc.	Predicting outcome with tamoxifen in breast cancer
DE10345836A1 (en)	2003-10-02	2005-04-21	Bayer Technology Services Gmbh	Method for simulating the interaction of chemical substances with living organisms
JP4732683B2 (en)	2003-12-29	2011-07-27	ユニバーサル・バイオ・リサーチ株式会社	Target substance detection method
JP4689660B2 (en)	2004-03-18	2011-05-25	ファンダツィオーネィルックスインスティチュートナツィオナレデイツモリ	4-Oxo-fenretinide used alone and in combination with fenretinide as a prophylactic and therapeutic agent for cancer
WO2005094363A2 (en)	2004-03-30	2005-10-13	New York University	System, method and software arrangement for bi-allele haplotype phasing
DE102004025534A1 (en)	2004-05-25	2005-12-15	Bayer Technology Services Gmbh	Method for (two-stage) dose and dosage finding
US8024128B2 (en)	2004-09-07	2011-09-20	Gene Security Network, Inc.	System and method for improving clinical decisions by aggregating, validating and analysing genetic and phenotypic data
US8147615B2 (en)	2004-11-05	2012-04-03	Infineon Technologies Ag	Method of fabricating semiconductor cleaners
KR20080013927A (en) *	2005-06-02	2008-02-13	바이오베일 라보라토리즈 인터내셔널 에스알엘	Modified release composition of one or more forms of venlafax
US20070122824A1 (en)	2005-09-09	2007-05-31	Tucker Mark R	Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime
EP1938231A1 (en)	2005-09-19	2008-07-02	BG Medicine, Inc.	Correlation analysis of biological systems
RU2318508C2 (en) *	2005-12-28	2008-03-10	Всеволод Иванович Киселев	Pharmaceutical composition for preventing and treating proliferative mammary gland diseases
FR2896896B1 (en)	2006-02-02	2009-09-25	Commissariat Energie Atomique	METHOD FOR CLASSIFYING EVENTS OR STATEMENTS IN TWO STEPS
DE102006028232A1 (en)	2006-06-20	2007-12-27	Bayer Technology Services Gmbh	Apparatus and method for calculating and providing a dose of medicament
HUE037109T2 (en)	2006-11-21	2018-08-28	Jina Pharmaceuticals Inc	Endoxifen for use in the treatment of cancer
US20090291134A1 (en)	2006-11-21	2009-11-26	Jina Pharmaceuticals, Inc.	Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
US8099298B2 (en)	2007-02-14	2012-01-17	Genelex, Inc	Genetic data analysis and database tools
WO2009108802A2 (en)	2008-02-26	2009-09-03	Purdue Research Foundation	Method for patient genotyping
WO2009120999A2 (en) *	2008-03-28	2009-10-01	Olema Pharmaceuticals, Inc.	Use of an endoxifen prodrug for treatment of breast cancer
US20100029734A1 (en) *	2008-05-06	2010-02-04	Ore Pharmaceuticals Inc.	Methods for breast cancer screening and treatment
AU2009267052B2 (en)	2008-06-30	2013-07-11	Tocagen Inc.	Formulations of 5-fluorocytosine and uses thereof
JP4517312B2 (en) *	2008-07-08	2010-08-04	ソニー株式会社	Memory access control device and imaging device
US20110136913A1 (en) *	2008-08-19	2011-06-09	Goetz Matthew P	Assessing and treating breast cancer patients
US8275442B2 (en)	2008-09-25	2012-09-25	Zeltiq Aesthetics, Inc.	Treatment planning systems and methods for body contouring applications
US7873482B2 (en)	2008-12-16	2011-01-18	Bruno Stefanon	Diagnostic system for selecting nutrition and pharmacological products for animals
US20120088247A1 (en)	2009-02-23	2012-04-12	Indian University Research & Technology Corporatio	Materials and methods for treating patients with taxoxifen
WO2011072244A1 (en) *	2009-12-10	2011-06-16	Mount Sinai School Of Medicine Of New York University	Method of treatment of breast cancer with tamoxifen
US9372198B2 (en)	2010-06-17	2016-06-21	Aradigm Corporation	Diagnosis of entry of gastrointestinal contents into respiratory tract of humans and animals
MX349974B (en) *	2010-08-26	2017-08-22	Ipca Laboratories Ltd *	Methods for the treatment or prophylaxis of thrombosis or embolism.
CA2839608C (en) *	2011-06-27	2020-07-14	Ipca Laboratories Limited	(7as,2's)-2-oxoclopidogrel as anti-thrombotic compounds
CN108048521B (en)	2012-04-02	2022-05-27	博格有限责任公司	Interrogative cell-based assays and uses thereof
EP2668945A1 (en)	2012-06-01	2013-12-04	Bayer Technology Services GmbH	Genotype and phenotype-based medicinal formulations
US9417221B2 (en)	2013-08-27	2016-08-16	International Business Machines Corporation	Food steganography

2012
- 2012-06-01 EP EP12170401.9A patent/EP2668945A1/en not_active Withdrawn
2013
- 2013-05-27 DK DK13725157.5T patent/DK2854789T3/en active
- 2013-05-27 SG SG10201610072UA patent/SG10201610072UA/en unknown
- 2013-05-27 JP JP2015514441A patent/JP6096289B2/en active Active
- 2013-05-27 PL PL13725157T patent/PL2854789T3/en unknown
- 2013-05-27 CN CN201910317702.5A patent/CN110075097A/en active Pending
- 2013-05-27 PT PT13725157T patent/PT2854789T/en unknown
- 2013-05-27 BR BR112014030059-3A patent/BR112014030059B1/en active IP Right Grant
- 2013-05-27 NZ NZ702849A patent/NZ702849A/en unknown
- 2013-05-27 ES ES13725157T patent/ES2744306T3/en active Active
- 2013-05-27 MX MX2014014596A patent/MX370304B/en active IP Right Grant
- 2013-05-27 EP EP13725157.5A patent/EP2854789B1/en active Active
- 2013-05-27 HU HUE13725157A patent/HUE045699T2/en unknown
- 2013-05-27 SG SG11201407791VA patent/SG11201407791VA/en unknown
- 2013-05-27 RU RU2014154140A patent/RU2683260C2/en active
- 2013-05-27 AU AU2013269793A patent/AU2013269793B2/en active Active
- 2013-05-27 CN CN201380040850.8A patent/CN104507464A/en active Pending
- 2013-05-27 WO PCT/EP2013/060824 patent/WO2013178565A1/en active Application Filing
- 2013-05-27 CA CA2875189A patent/CA2875189C/en active Active
- 2013-05-27 KR KR1020147036212A patent/KR102129043B1/en active Active
- 2013-05-27 US US14/403,823 patent/US10285958B2/en active Active
- 2013-05-31 AR ARP130101928 patent/AR091234A1/en unknown
- 2013-05-31 TW TW102119266A patent/TWI644666B/en active
- 2013-06-01 SA SA113340607A patent/SA113340607B1/en unknown
2014
- 2014-11-30 IL IL235988A patent/IL235988B/en active IP Right Grant
2015
- 2015-08-17 HK HK15107896.3A patent/HK1207296A1/en unknown
2016
- 2016-11-09 JP JP2016219156A patent/JP2017048234A/en active Pending
2017
- 2017-01-31 US US15/420,733 patent/US20170326080A1/en not_active Abandoned
- 2017-06-16 US US15/625,553 patent/US20170326081A1/en not_active Abandoned
2020
- 2020-04-30 AR ARP200101246A patent/AR118842A2/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP6096289B2 (en)	2017-03-15
US20170326081A1 (en)	2017-11-16
AU2013269793B2 (en)	2018-03-01
IL235988A0 (en)	2015-01-29
EP2854789A1 (en)	2015-04-08
TWI644666B (en)	2018-12-21
EP2854789B1 (en)	2019-06-26
KR102129043B1 (en)	2020-07-01
JP2017048234A (en)	2017-03-09
HK1207296A1 (en)	2016-01-29
AR091234A1 (en)	2015-01-21
RU2683260C2 (en)	2019-03-27
BR112014030059A2 (en)	2017-07-25
SA113340607B1 (en)	2018-05-09
ES2744306T3 (en)	2020-02-24
AU2013269793A1 (en)	2015-01-22
CN104507464A (en)	2015-04-08
HUE045699T2 (en)	2020-01-28
BR112014030059B1 (en)	2022-12-06
CA2875189C (en)	2020-09-22
IL235988B (en)	2018-11-29
PT2854789T (en)	2019-09-18
JP2015519350A (en)	2015-07-09
NZ702849A (en)	2016-09-30
CN110075097A (en)	2019-08-02
WO2013178565A1 (en)	2013-12-05
AR118842A2 (en)	2021-11-03
US20170326080A1 (en)	2017-11-16
RU2014154140A (en)	2016-07-27
US10285958B2 (en)	2019-05-14
CA2875189A1 (en)	2013-12-05
KR20150022894A (en)	2015-03-04
MX2014014596A (en)	2015-03-03
US20150174082A1 (en)	2015-06-25
PL2854789T3 (en)	2019-12-31
MX370304B (en)	2019-12-09
TW201400109A (en)	2014-01-01
DK2854789T3 (en)	2019-09-16
SG11201407791VA (en)	2015-01-29
EP2668945A1 (en)	2013-12-04

Publication	Publication Date	Title
HK1208372A1 (en)	2016-03-04	Liquid formulation
ZA201501930B (en)	2016-01-27	Pharmaceutical composition
GB201215289D0 (en)	2012-10-10	Nanoparticle formulation
EP2832730A4 (en)	2015-09-09	Mirabegron-containing pharmaceutical composition
HK1205146A1 (en)	2015-12-11	Pharmaceutical formulation
HK1202445A1 (en)	2015-10-02	New formulation
ZA201306000B (en)	2014-04-30	Stable formulation
HK1205679A1 (en)	2015-12-24	Nicotine formulation
HK1205683A1 (en)	2015-12-24	Pharmaceutical formulation having improved stability
LT3473255T (en)	2022-03-10	Pharmaceutical formulation comprising ciclesonide
ZA201502987B (en)	2016-11-30	Pharmaceutical composition
HK1207296A1 (en)	2016-01-29	Genotype- or phenotype-based drug formulation
HK1206269A1 (en)	2016-01-08	Pharmaceutical formulation comprising bendamustine
EP2897590A4 (en)	2016-05-04	Pharmaceutical composition
SG11201406097SA (en)	2014-11-27	Capsule formulation
HK1204945A1 (en)	2015-12-11	Pharmaceutical formulation containing flupirtin
HK1209339A1 (en)	2016-04-01	Pharmaceutical formulations
IL244316A0 (en)	2016-04-21	Novel drug formulation
GB201211247D0 (en)	2012-08-08	Improved formulation
IL234771B (en)	2019-10-31	Nicotine formulation
ZA201400751B (en)	2014-12-25	Pharmaceutical composition
GB201211406D0 (en)	2012-08-08	Pharmaceutical formulations
GB201211403D0 (en)	2012-08-08	Pharmaceutical formulations